Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

02-11-2017 10:20

Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the Boehringer Ingelheim Venture Fund (BIVF) will join the Company´s syndicate of strategic and financial investors which was established through a Series A financing round in 2016.

PDF-file 116kb

Dutch version - French version - German version